Abstract: In some embodiments, a filter membrane module includes at least one ceramic filter element made of a sintered, porous, ceramic structure, a potting material for potting the ceramic filter element, the potting material having an uncured state and a cured state, and a housing, wherein the potting material is a thermoplastic or a thermosetting plastic that in the cured state has a tensile strength in the range of about 2-65 MPa and a thermal expansion coefficient in the range of about 55-260×10?6/K, and a penetration depth of the potting material into the structure of the filter element is in the range of 0.24 mm to 3.0 mm, and a shrinkage after curing is less than 1.24%.

Abstract: The present description includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the description includes a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. The target protein contemplated within the description comprises an androgen receptor. Compounds of the present description may be used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.

Abstract: The present invention includes compounds that act as degraders of a target protein, wherein degradation is independent of the class of the target protein or its localization. In certain embodiments, the invention comprises a compound comprising a protein degradation moiety covalently bound to a linker, wherein the ClogP of the compound is equal to or higher than 1.5. In other embodiments, the target protein contemplated within the invention comprises a posttranslational modified protein or intracellular protein. In yet other embodiments, compounds of the present invention are used to treat disease states wherein protein degradation is a viable therapeutic approach, such as cancer or any sort of oxidative stress disease state.

Abstract: The present invention refers to bisphosphonate and phosphonate/phosphate compounds of Formulae I and its use as inhibitors of aSMase enzyme activity.